LC determination of rosiglitazone in bulk and pharmaceutical formulation

A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma

“…To simplify the process, we decided to establish a method to determine them simultaneously. Some analytical methods have been presented for individual measurement of RSG [7][8][9][10][11][12][13][14][15][16][17] and gemfibrozil [18][19][20][21], such as high performance liquid chromatography with ultraviolet (HPLC-UV) detection, fluorescence detection (HPLC-FD) and liquid chromatography-tandem mass spectrometry (HPLC-MS -MS). But the drawbacks of the HPLC-UV methods involving the low sensitivity, long analysis time and complex sample preparation limit their usage in routine therapeutic drug monitoring (TDM) and pharmacokinetic interaction study of the two drugs.…”

Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: Application to a pharmacokinetic study

“…To detect rosiglitazone in biological samples, several methods using high-performance liquid chromatography (HPLC) with ultraviolet or fluorescence detection have been developed [9][10][11][12][13][14][15]. However, these methods require time-consuming and laborious extraction procedures or relatively large sample volumes (∼1 ml), as well as lengthy chromatographic run times, limiting their throughput capacity and sensitivity.…”

Development and Validation of HPTLC Densitometry Method for Simultaneous Estimation of Rosiglitazone and Glimepiride in Fixed Tablet Dosage Form

“…), India and Medley Pharmaceuticals Ltd., Bari Brahmana, Jammu, India, respectively. 4 , LC/MS HPLC in human plasma 5 , LC in pharmaceutical formulation and human plasma 6,7 , MEKC and HPLC 8 , solid phase extraction coupled with LC-MS/MS 9 , HPTLC 10 methods have been reported for analytical monitoring of ROSI individually and with other drugs. Glimepiride, chemically 3-ethyl-4-methyl-N-(4-(N-(1-(4-methylcyclohexylamino)vinyl)-sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide, is a sulphonyl-urea antidiabetic drug and its structure is shown in Fig.…”